GleamWall
中文EN

BMRN BIOMARIN PHARMACEUTICAL INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1048477 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY18.1%
TTM net income YoY-103.7%
TTM EPS YoY-103.7%
Revenue 3-yr CAGR16.5%
Net income 3-yr CAGR—

Margins

Gross margin76.0%
Operating margin3.1%
Net margin-0.5%
FCF margin15.3%
EBITDA margin4.7%

Returns

ROE-0.3%
ROA-0.2%
ROIC (approx.)0.8%
Asset turnover0.38x

Leverage & solvency

Liabilities / assets45.9%
Debt / equity0.67x
Current ratio2.44x
Interest coverage0.89x

Cash quality & payout

Operating cash flow / net income-35.40x
Accruals ratio-7.3%
Payout ratio—
Capex / revenue3.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.02B$989.71M$766.21M$874.57M$776.13M$825.41M$745.14M$747.31M
Cost of revenue$205.42M$202.79M$195.00M$275.71M$140.09M$150.09M$151.56M$136.14M
Gross profit$819.23M$786.91M$571.21M$598.86M$636.05M$675.32M$593.59M$611.17M
R&D expense$180.53M$206.95M$178.80M$192.41M$188.51M$161.31M$158.73M$173.51M
SG&A expense$333.64M$395.55M$258.29M$446.21M$268.42M$232.28M$206.12M$266.61M
Operating income-$82.08M$110.92M$129.64M-$44.61M-$46.69M$276.89M$223.89M$161.41M
Interest expense$55.23M$60.73M$9.57M$2.78M$2.39M$2.39M$2.39M$2.58M
Pretax income-$131.77M$61.38M$141.20M-$27.15M-$26.32M$297.87M$238.09M$169.64M
Income tax-$8.94M$16.62M$35.68M$19.42M$4.42M$57.34M$52.40M$44.70M
Net income-$122.83M$44.76M$105.53M-$46.57M-$30.74M$240.53M$185.69M$124.94M
EBITDA-$71.88M$120.52M$146.05M-$24.17M-$36.09M$287.49M$245.96M$185.01M
EPS (basic)-0.630.230.55—-0.161.250.97—
EPS (diluted)-0.630.230.54—-0.161.230.95—
Weighted avg. shares (diluted)193.59M194.47M197.67M—192.03M197.09M196.47M—
Balance sheet
Cash & equivalents$736.01M$874.00M$2.22B$1.31B$1.25B$1.21B$1.05B$942.84M
Short-term investments$0$0$0$248.93M$227.73M$218.31M$223.53M$194.86M
Receivables$1.08B$1.06B$903.91M$908.21M$790.27M$855.86M$739.18M$660.53M
Inventory$1.80B$1.78B$1.27B$1.30B$1.38B$1.34B$1.27B$1.23B
Current assets$3.92B$3.97B$4.61B$3.95B$3.85B$3.81B$3.47B$3.23B
PP&E, net$980.08M$989.99M$958.07M$952.51M$1.04B$1.03B$1.03B$1.04B
Goodwill$666.37M$655.75M$196.20M$196.20M$196.20M$196.20M$196.20M$196.20M
Intangibles$4.78B$4.88B$204.66M$213.84M$233.11M$239.62M$247.35M$255.28M
Total assets$11.57B$11.72B$8.59B$7.59B$7.61B$7.46B$7.15B$6.99B
Current liabilities$1.60B$1.66B$793.15M$759.03M$798.44M$684.25M$628.21M$606.99M
Short-term debt$658.72M$658.20M—$0————
Long-term debt$3.51B$3.53B$1.43B$597.18M————
Total debt$4.17B$4.19B$1.43B$597.18M————
Total liabilities$5.31B$5.40B$2.38B$1.51B$1.56B$1.43B$1.35B$1.33B
Shareholders' equity$6.26B$6.32B$6.21B$6.09B$6.06B$6.03B$5.79B$5.66B
Net debt$3.44B$3.31B-$792.15M-$714.50M————
Shares outstanding193.68M193.54M193.27M192.30M192.10M192.00M191.76M190.76M
Cash flow statement
Operating cash flow$188.21M$168.11M$220.65M$99.64M$368.69M$185.27M$174.39M$185.63M
Capital expenditure$28.29M$28.82M$20.92M$40.72M$28.45M$17.10M$16.77M$19.53M
Free cash flow$159.92M$139.29M$199.73M$58.92M$340.24M$168.17M$157.63M$166.10M
Investing cash flow-$306.90M-$5.10B$725.53M-$42.45M-$330.96M-$12.59M-$28.24M$76.40M
Financing cash flow-$18.83M$2.74B$813.17M$3.16M-$2.17M-$4.60M-$38.78M$2.86M
Depreciation & amortization$10.20M$9.60M$16.41M$20.44M$10.60M$10.60M$22.07M$23.61M
Stock-based compensation$53.53M$75.69M$43.46M$46.91M$49.27M$47.53M$37.70M$51.92M

Free plan shows the latest 8 periods; Pro shows all 71 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.